## GEHC: GE HealthCare Technologies Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 5.4% in lower entry zone (4.0-10.0%), top quartile (77th pct) cross-sectional ranking. Short-term MRS_5 (1.2%) confirms momentum alignment. Outperforming sector by 5.7%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($79.44)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. URMC and GE HealthCare partner on seven-year Care Alliance to expand imaging capabilities**
- Source: DOTmed | 20251211T141829 | Bullish | Relevance: 100%
- The University of Rochester Medical Center (URMC) and GE HealthCare have initiated a seven-year Care Alliance to significantly enhance URMC's diagnostic imaging and patient monitoring capabilities. This collaboration involves upgrading technology with AI-powered MR systems and SPECT/CT scanners, expanding precision medicine through theranostics and radiopharmaceutical development, and standardizing patient monitoring equipment across the UR Medicine health system. The partnership aims to improve patient access, efficiency, and care quality across the Finger Lakes region.

**2. Sant' Andrea University Hospital to Integrate GE HealthCare and Tribun Health's Enterprise Imaging and Digital Pathology Solutions to Help Improve Patient Care**
- Source: The News Journal | 20251211T050832 | Bullish | Relevance: 100%
- Sant' Andrea University Hospital, affiliated with Sapienza University of Rome, will integrate GE HealthCare's Enterprise Imaging platform with Tribun Health's CaloPix速 digital pathology solution. This collaboration aims to unify radiology and pathology into an AI-ready environment, accelerating diagnostics and improving cancer patient outcomes. The hospital is the first in Lazio to implement full digital pathology, supported by significant investment.

**3. Sant' Andrea University Hospital to Integrate GE HealthCare and Tribun Health's Enterprise Imaging and Digital Pathology Solutions to Help Improve Patient Care**
- Source: Tallahassee Democrat | 20251211T040827 | Bullish | Relevance: 100%
- Sant' Andrea University Hospital is set to integrate GE HealthCare's Enterprise Imaging platform and Tribun Health's CaloPix速 digital pathology solution. This collaboration aims to unify radiology and pathology into an AI-ready environment, accelerating diagnostics and improving cancer patient outcomes. The investment, partially funded by the National Recovery and Resilience Plan, positions Sant' Andrea at the forefront of data-driven cancer care in Lazio.

**4. Sant' Andrea University Hospital to Integrate GE HealthCare and Tribun Health's Enterprise Imaging and Digital Pathology Solutions to Help Improve Patient Care**
- Source: Rock Hill Herald | 20251210T141029 | Bullish | Relevance: 100%
- Sant' Andrea University Hospital is partnering with GE HealthCare and Tribun Health to integrate enterprise imaging and digital pathology solutions, aiming to enhance patient care, particularly in oncology. This collaboration will unify radiology and pathology into an AI-ready environment using GE HealthCare's Datalogue platform and Tribun Health's CaloPix速 digital pathology solution. The initiative seeks to accelerate diagnostics, improve multidisciplinary collaboration, and streamline cancer care pathways for patients.

**5. Sant' Andrea University Hospital to Integrate GE HealthCare and Tribun Health's Enterprise Imaging and Digital Pathology Solutions to Help Improve Patient Care**
- Source: Fox 59 | 20251210T141029 | Bullish | Relevance: 100%
- Sant' Andrea University Hospital is integrating GE HealthCare's Enterprise Imaging platform and Tribun Health's CaloPix速 digital pathology solution to unify radiology and pathology. This collaboration aims to create a seamless, AI-ready environment for data-driven cancer care, accelerating diagnostics, and improving patient outcomes. The investment, partially funded by the National Recovery and Resilience Plan, positions Sant' Andrea at the forefront of digital pathology in Lazio.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Citigroup | $88 | $83 | +6% |
| 2025-12-11 | Jefferies | $105 | $95 | +11% |
| 2025-11-21 | BTIG | $87 | $87 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Citigroup | main | Neutral |
| 2025-12-11 | Jefferies | main | Buy |
| 2025-11-21 | BTIG | reit | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.2%)
- Blackrock Inc.: 8.0% (+1.9%)
- Dodge & Cox Inc.: 6.0% (+16.8%)
- Capital Research Glo: 5.5% (+25.0%)
- State Street Corpora: 4.3% (-0.1%)

### Key Risks

1. Volume divergence: price rising (+0.1% MRS) on declining volume (66% of avg) suggests distribution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 2.58 signals overvaluation risk, limited margin of safety. Forward P/E 17.0x stretched relative to 8% growth. Quality metrics strong (ROE 24%). Analyst sentiment positive (2 raises, avg +8%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $38.3B |
| Beta | 1.24 |
| 52W Range | $57.65 - $94.80 |
| Short Interest | 3.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.58 |
| Forward P/E | 17.0 |
| Current P/E | 18.5 |
| YoY Growth | 8.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at 5.4% (minimal 5-day change). Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 77th percentile. MRS_5 at 1.2% confirms short-term momentum alignment. AM_20 at 5.7% shows strong absolute momentum above own 20MA. Outperforming sector by 5.7pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 5.38% (CS: 77) | Strong |
| RSI_14 | 61.3 | Neutral |
| MACD Histogram | 0.48 | Bullish |
| vs SMA20 | 1.057x | Above |
| vs SMA50 | 1.094x | Above |
| vs SMA200 | 1.126x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $83.96
- **Stop Loss:** $79.44 (5.4% risk)
- **Target:** $90.74 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 221
- **Position Value:** $18,555.16
- **Portfolio %:** 18.56%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.05 | $1.07 | +2.2% |
| 2025Q2 | $0.92 | $1.06 | +15.4% |
| 2025Q1 | $0.91 | $1.01 | +10.6% |
| 2024Q4 | $1.26 | $1.45 | +14.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*